Introduction {#s1}
============

β-N-acetylhexosaminidases (EC 3.2.1.52) are responsible for catalyzing the hydrolysis of β-linked N-acetyl-D-hexosamine unit from non-reducing ends of glycans, glycoproteins, and glycolipids (Henrissat and Davies, [@B12]; Liu et al., [@B22]). Based on the Carbohydrate Active Enzymes database (CAZy, <http://www.cazy.org/>), most β-N-acetylhexosaminidases are classified into three glycosyl hydrolase families, namely, GH3, GH20, and GH84 (Henrissat and Davies, [@B12]; Cantarel et al., [@B4]). These enzymes are widely distributed in many organisms and are involved in various physiological functions (Intra et al., [@B14]; Liu et al., [@B22]). Remarkably, GH84 human O-GlcNAcase (hOGA) has drawn significant attention and has been considered as a potential target for drug development (Bergeron-Brlek et al., [@B3]; Kong et al., [@B19]; Roth et al., [@B27]; Shen et al., [@B28]).

GH84 human O-GlcNAcase (hOGA) is a 103-kDa multidomain protein that can catalyze the removal of β-linked N-acetyl-D-glucosamine (GlcNAc) from serine and threonine residues (Elsen et al., [@B10]). The hOGA combined with human O-GlcNAc transferase (hOGT) regulate the dynamic removal and addition of O-GlcNAc for hundreds of nucleocytoplasmic proteins (Yuzwa et al., [@B36]; Elsen et al., [@B10]). This modification has also been reported to compete with protein phosphorylation (Yuzwa et al., [@B36]). Perturbation of O-GlcNAc cycling has been implicated in many diseases such as Alzheimer\'s disease (Yuzwa and Vocadlo, [@B37]), type II diabetes (McClain et al., [@B25]), and cancer (Ferrer et al., [@B11]). Since they share the same substrate-assisted catalytic mechanism, GH20 human β-N-acetylhexosaminidase (HsHex) can hydrolyze the terminal non-reducing GalNAc from GM2 ganglioside (Mahuran, [@B24]). Dysfunction of HsHex results in GM2 ganglioside storage disorders in the lysosome, which leads to Tay--Sachs and Sandhoff disease (Mahuran, [@B24]).

Potent hOGA inhibitors with good selectivity (over HsHex) are greatly important to study the physiological functions of hOGA (Yuzwa et al., [@B36]; Dorfmueller et al., [@B8]). To date, a number of hOGA inhibitors have been reported, such as PUGNAc (Macauley et al., [@B23]), NAG-thiazoline (NGT) (Krejzova et al., [@B21]), Streptozotocin (Toleman et al., [@B32]), Nagstatin (Aoyagi et al., [@B1]; Terinek and Vasella, [@B31]), iminocyclitols (Bergeron-Brlek et al., [@B3]), and thioglycosyl--naphthalimides (Chen et al., [@B6]; Shen et al., [@B28],[@B29]). Among these inhibitors, NGT is synthesized as an analog of NAG-oxaoline (which is a reaction intermediate of the substrate-assisted mechanism) (Knapp et al., [@B18]) with low selectivity toward hOGA (*K*~i~ = 180 nM) (Krejzova et al., [@B21]) and HsHex (*K*~i~ = 70 nM) (Knapp et al., [@B18]). To improve the selective inhibition against hOGA, Thiamet-G bearing an ethylamino substituent on the thiazoline ring was designed and found to exhibit excellent potency (*K*~i~ = 21 nM against hOGA) and selectivity (*K*~i~ = 750 μM against HsHex) (Yuzwa et al., [@B36]) ([Figure 1](#F1){ref-type="fig"}). This modification indicates that hOGA possesses a larger catalytic active pocket than HsHex, and the appropriate increase of the methyl group of thiazoline could improve the binding affinity toward hOGA. The potent β-N-acetylhexosaminidase inhibitor Nagstatin, was originally isolated from fermentation broth of *Streptomyces amakusaensis* (Aoyagi et al., [@B1]). Subsequently, Gluco-nagstatin was reported by Terinek with *K*~i~ values of 420 nM against hOGA and 10 nM against HsHex (Terinek and Vasella, [@B31]). Furthermore, GlcNAcstatin C, bearing the 2-isobutyramido on the glycosyl moiety and phenemyl on the iminazole group was found to be an extremely potent hOGA inhibititor (*K*~i~ = 4.4 nM) with 164-fold selectivity compared to HsHex (*K*~i~ = 550 nM) (Dorfmueller et al., [@B8]) ([Figure 1](#F1){ref-type="fig"}). These results suggest that enlargement of the substituent at the 2-position of the glycosyl moiety of Nagstatin leads to an increase of both the inhibitory efficiency and selectivity toward hOGA. These classical inhibitors exhibited significant potency against hOGA; however, further applications may be limited by the large-scale preparation (complex synthetic methods) and drug-like properties (Dorfmueller et al., [@B8]; Krejzova et al., [@B21]).

![Optimization strategy of thioglycosyl--naphthalimides toward hOGA.](fchem-07-00533-g0001){#F1}

In our previous research, we presented thioglycosyl--naphthalimides **15b** (**1**, *K*~i~ = 3.8 μM against hOGA, *K*~i~ = 30.4 μM against HsHexB) and **5c** (**2**, *K*~i~ = 3.46 μM against hOGA, *K*~i~ \> 100 μM against HsHexB) as promising lead compounds for hOGA (Chen et al., [@B6]; Shen et al., [@B28]). Subsequently, modification of the 4-substituent group at the naphthalimide of **15b** led to the synthesis of **13r** (**3**, *K*~i~ = 0.6 μM against hOGA; *K*~i~ \>100 μM against HsHexB), bearing a 4-piperidylnaphthalimide moiety, which exhibited higher potency and selectivity toward hOGA (Shen et al., [@B29]) ([Figure 1](#F1){ref-type="fig"}). This indicated that the 4-substituent at the naphthalimide scaffold critically affects the activity and selectivity of thioglycosyl--naphthalimides against hOGA (Shen et al., [@B29]). Considering the important functions of hOGA for the post-translational modification within eukaryotic cells, this study further attempted to optimized the structure of **5c** (**2**) to continue to increase the efficiency and selectivity against hOGA. The utilized strategy first synthesized 4-substituted naphthalimide thioglycosides and evaluated their inhibitory activities against hOGA and HsHexB. Thus, suitable 4-substituents (on the naphthalimide moiety) were identified through structure-activity relationship studies. Then, we focused on the optimization of the 2-acetamido group at the glycosyl moiety to obtain novel thioglycosyl--naphthalimides hOGA inhibitors with increased potency and selectivity ([Figure 1](#F1){ref-type="fig"}). Accordingly, several classes of thioglycosyl--naphthalimides bearing amide linkers were synthesized and their inhibitory activities against hOGA and HsHexB were evaluated.

Results and Discussion {#s2}
======================

Synthesis of Thioglycosyl--naphthalimides 10a-10d
-------------------------------------------------

As shown in [Scheme 1](#S1){ref-type="scheme"}, compounds **5a-5d** were prepared according to literature methods (Shen et al., [@B29]) and reacted with chloracetyl chloride to afford **6a-6d**. Meanwhile, the key intermediate **8** was obtained from N-acetyl-D-glucosamine as previously described (Paul and Korytnyk, [@B26]). Then, treatment of **6a-6d** with thiol **8** in 2:1 acetone/H~2~O mixture yielded precursors **9a-9d**. Finally, deacetylation of **9a-9d** via methylamine catalysis formed the target products **10a-10d** ([Scheme S1](#S1){ref-type="scheme"}).

![Synthesis of thioglycosyl--naphthalimides **10a-10d**. (i) *tert*-butyl (3-aminopropyl) carbamate, EtOH; (ii) DCM, CF~3~COOH; (iii) 2-chloroacetyl chloride, Et~3~N, DCM; (iv) AcCl; (v) thiourea, acetone; (vi) Na~2~S~2~O~5~, DCM, H~2~O; (vii) K~2~CO~3~, acetone, H~2~O; (viii) CH~3~NH~2~, MeOH. R~1~ is defined in [Table 1](#T1){ref-type="table"}.](fchem-07-00533-g0004){#S1}

Inhibitory Activities of 10a-10d Against hOGA and HsHexB
--------------------------------------------------------

Inhibitory activities of target compounds **10a-10d** against hOGA and HsHexB were evaluated *in vitro* ([Table 1](#T1){ref-type="table"}). The results showed that the 4-substituted group on the naphthalimide moiety significantly influenced the potency of thioglycosyl--naphthalimides against hOGA. Specifically, thioglycosyl--naphthalimides bearing OMe (**10b**) and N(CH~3~)~2~ (**10c**) substituents exhibited an activity decrease compared to that of naphthalimides bearing no 4-substituents (lead compound **2**). Thioglycosides bearing the 4-bromo (**10a**) and 4-piperidyl (**10d**) on the naphthalimide moiety improved the inhibitory potency. Compound **10a** in particular exhibited the highest inhibitory efficiency against hOGA with a *K*~i~ value of 0.61 μM (indicating an almost 6-fold increase in potency) and excellent selectivity (*K*~i~ \>100 μM against HsHexB).

###### 

Inhibitory activities of **10a-10d** against hOGA and HsHexB.

  ![](fchem-07-00533-i0001.jpg)                                                                     
  ------------------------------- ------------- ------------ ------------ ------------------------- -----------
  **10a**                         Br            98.7 ± 0.3   36.5 ± 0.8   **0.61** **±** **0.02**   **\>100**
  **10b**                         OMe           90.6 ± 0.5   49.2 ± 1.4   4.43 ± 0.21               \>100
  **10c**                         N(CH~3~)~2~   84.4 ± 1.7   36.9 ± 0.2   9.72 ± 0.49               \>100
  **10d**                         Piperidyl     93.1 ± 0.2   32.8 ± 2.7   **1.42** **±** **0.02**   **\>100**
  **2**                           H             97.6 ± 0.9   45.5 ± 0.5   3.46 ± 0.11               \>100

*Bold values indicate bioassay data of compounds with better activity*.

Optimization of Inhibitors 10a and 10d
--------------------------------------

Compounds with higher inhibitory potency toward hOGA (**10a** and **10d**), were selected for further structural optimization. Considering that hOGA has a larger catalytic pocket than HsHex and can accommodate more bulky groups near the 2-acetamide of related substrates (Dorfmueller et al., [@B8]; Igual et al., [@B13]), we then focused on investigating the effect of 2-substituents at the glycosyl moiety on the inhibitory activity of hOGA. Accordingly, the Ph, 4-FPh, OBn, Et, *n*-Pr, *i*-Pr, CF~3~, and NHCH~3~ substituents were introduced into the position of the methyl group of 2-acetamido. The synthetic routes to thioglycosyl--naphthalimides **16a-16o** have been outlined in [Scheme 2](#S2){ref-type="scheme"}, and the specific synthesis methods are shown in [Scheme S2](#S2){ref-type="scheme"}.

![Synthesis of thioglycosyl--naphthalimides **16a-16o**. (i) *p*-anisaladehyde, NaOH, H~2~O; (ii) Py, Ac~2~O; (iii) acetone, HCl, H~2~O; (iv) Et~3~N, CH~2~Cl~2~, R~2~COCl for **13a-13h**; Et~3~N, CH~2~Cl~2~, TFAA for **13i**; (v) HBr, CH~3~COOH, CH~2~Cl~2~; (vi) thiourea, acetone; (vii) Na~2~S~2~O~5~, CH~2~Cl~2~, H~2~O; (viii) K~2~CO~3~, acetone, H~2~O, **6a** or **6d**; (viii) CH~3~NH~2~, MeOH. R~1~ and R~2~ are defined in [Table 2](#T2){ref-type="table"}.](fchem-07-00533-g0005){#S2}

Inhibitory Activities of 16a-16o Against hOGA and HsHexB
--------------------------------------------------------

Assays of the inhibitory activities of **16a-16o** against hOGA and HsHexB are presented in [Table 2](#T2){ref-type="table"}. Enlarging the size of the methyl group of 2-acetamido led to a decrease in inhibitory activity against hOGA, and larger substituents led to lower efficiency. Briefly, slightly increasing the size of the Me group (**10d**) to Et (**16d**) resulted in a minor decrease in inhibitory potency. Modification of Me to CF~3~, NHCH~3~, *n*-Pr, and *i*-Pr reduced the activity to a greater degree (from **10d** to **16g**, **16h**, **16e**, and **16f**). Upon increasing the size from Me (**10d**) to Ph (**16a**), 4-FPh (**16b**), and OBn (**16c**) led to the loss of activity against hOGA. Moreover, the 4-bromo group on the naphthalimide moiety of these thioglycosides was more beneficial than 4-piperidyl for increasing the inhibitory activity toward hOGA (compared to **16l-16o** and **16d-16g**). All target compounds **16a-16o** exhibited low inhibitory activity against HsHexB (*K*~i~ \>100 μM), which indicates that these thioglycosides possess promising selectivity toward hOGA. Among **16a-16o**, compound **16l** showed the highest potency against hOGA with a *K*~i~ value of 0.72 μM.

###### 

Inhibitory activities of **16a-16o** against hOGA and HsHexB.

  ![](fchem-07-00533-i0002.jpg)                                                                             
  ------------------------------- ----------- --------- ------------ ------------ ------------------------- -----------
  **16a**                         Piperidyl   Ph        22.0 ± 0.5   12.2 ± 0.2   \>100                     \>100
  **16b**                         Piperidyl   4-FPh     50.9 ± 0.8   15.8 ± 0.4   \>100                     \>100
  **16c**                         Piperidyl   OBn       9.7 ± 0.7    2.0 ± 1.1    \>100                     \>100
  **16d**                         Piperidyl   Et        88.0 ± 1.5   28.7 ± 2.0   **1.69** **±** **0.05**   **\>100**
  **16e**                         Piperidyl   n-Pr      78.9 ± 1.9   24.6 ± 1.5   12.80 ± 0.27              \>100
  **16f**                         Piperidyl   i-Pr      72.2 ± 0.3   21.4 ± 0.5   23.58 ± 0.43              \>100
  **16g**                         Piperidyl   CF~3~     82.7 ± 1.0   6.4 ± 0.7    6.37 ± 0.09               \>100
  **16h**                         Piperidyl   NHCH~3~   85.5 ± 1.5   25.2 ± 0.3   6.60 ± 0.22               \>100
  **16j**                         Br          Ph        41.1 ± 0.6   49.1 ± 1.4   \>100                     \>100
  **16k**                         Br          4-FPh     48.0 ± 0.9   48.5 ± 1.7   \>100                     \>100
  **16l**                         Br          Et        97.7 ± 2.2   41.8 ± 1.0   **0.72** **±** **0.01**   **\>100**
  **16m**                         Br          n-Pr      97.1 ± 1.3   39.8 ± 2.3   4.36 ± 0.21               \>100
  **16n**                         Br          i-Pr      87.8 ± 0.4   37.0 ± 0.4   6.92 ± 0.10               \>100
  **16o**                         Br          CF~3~     90.9 ± 0.2   37.7 ± 0.9   4.62 ± 0.18               \>100
  **10d**                         Piperidyl   Me        93.1 ± 0.2   32.8 ± 2.7   **1.42** **±** **0.02**   **\>100**
  **10a**                         Br          Me        98.7 ± 0.3   36.5 ± 0.8   **0.61** **±** **0.02**   **\>100**

*Bold values indicate bioassay data of compounds with better activity*.

New Method for the Synthesis of Thioglycosyl--naphthalimide 16h
---------------------------------------------------------------

Deacetylation of **15i**, bearing trichloroethoxycarbonyl (Troc) group, with methylamine catalysis at room temperature for 48 h did not obtain **16i**. Instead, thioglycoside **16h** bearing methylaminocarbonyl formed ([Scheme 3](#S3){ref-type="scheme"}). This suggests that the mechanism for this reaction is that methylamine nucleophilic attacks the isothiocyanate intermediate (yielded by the well-known base-promoted elimination of trichloroethanol) to produce the corresponding urea compounds (Azad et al., [@B2]). Review of previous literature, we found that the occurrence of this reaction required high pressure (Azad et al., [@B2]), high temperature (Jeong et al., [@B17]), or catalyst (Simard et al., [@B30]; Kono et al., [@B20]; Jang and Kim, [@B16]; Zhang et al., [@B38]) conditions. Accordingly, a new and more practical approach for the synthesis of ureido glycosides at room temperature and normal pressure without catalyst is reported here.

![New method for the synthesis of thioglycosyl--naphthalimides **16h** (i) CH~3~NH~2~, MeOH.](fchem-07-00533-g0006){#S3}

Synthesis of Ureido Glycosides 17a-17d and Their Activities Against hOGA and HsHexB
-----------------------------------------------------------------------------------

To verify the universality and reliability of this method, acetyl-protected precursors **15i** and **15p** were reacted with different amines ([Scheme 4](#S4){ref-type="scheme"}). Successfully, four new ureido glycosides (**17a-17d**) were synthesized through this reaction route. The specific synthesis methods can be found in [Scheme S4](#S4){ref-type="scheme"} and the substituents R~1~ and R~3~ are defined in [Table 3](#T3){ref-type="table"}.

![Synthesis of ureido glycosides **17a-17d**. (i) R~3~NH~2~, MeOH. R~1~, and R~3~ are defined in [Table 3](#T3){ref-type="table"}.](fchem-07-00533-g0007){#S4}

###### 

Inhibitory activities of **17a-17d** against hOGA and HsHexB.

  ![](fchem-07-00533-i0003.jpg)                                                                          
  ------------------------------- ----------- ------ ------------ ------------ ------------------------- -----------
  **17a**                         Piperidyl   Et     68.6 ± 0.8   25.9 ± 0.3   12.01 ± 0.30              \>100
  **17b**                         Piperidyl   n-Pr   66.3 ± 0.6   22.7 ± 0.2   13.83 ± 0.02              \>100
  **17c**                         Br          Me     96.7 ± 1.6   40.7 ± 0.7   **2.17** **±** **0.13**   **\>100**
  **17d**                         Br          Et     83.5 ± 0.9   26.3 ± 1.1   7.11 ± 0.01               \>100
  **16h**                         Piperidyl   Me     85.5 ± 1.5   25.2 ± 0.3   6.60 ± 0.22               \>100

*Bold values indicate bioassay data of compounds with better activity*.

Analysis of **17a-17d** against hOGA indicated that the inhibitory potency of these compounds was associated with the size of 2-position substituents on the glycosyl moiety. In detail, enlargement of the size of the NHCH~3~ (**16h** or **17c**) to NHC~2~H~5~ (**17a** or **17d**) resulted in a 2 to 3-fold decrease in inhibitory activity. Continuing to increase of the size of the substituents from NHC~2~H~5~ (**17a**) to NHC~3~H~7~ (**17b**) showed a minor activity loss (the *K*~i~ value increased from 12.01 μM to 13.83 μM). Further comparison of **16d** (bearing CH~2~CH~3~) and **16h** (bearing NHCH~3~) showed that the basic substituent at the 2-position of the glycosyl moiety decreased the potency against hOGA (reduced by about 4-fold), which suggests that the 2-ureido group on the glycosyl moiety was not beneficial for the improvement of the activity of thioglycosyl-naphthalimides toward hOGA. Additionally, the presence of the 4-bromo group on the naphthalimide moiety also demonstrated a more effective potency than 4-piperidyl in these ureido glycosides **17a-17d**.

Inhibitory Mechanism of the Thioglycosyl--naphthalimides Toward hOGA
--------------------------------------------------------------------

To understand the inhibitory mechanism of these thioglycosides toward hOGA, the highly potent inhibitors **10a** and **10d** were selected for kinetic studies via Dixon plots. As shown in [Figure 2](#F2){ref-type="fig"}, the trendlines drawn for each concentration of substrate meet in quadrant two, suggesting that thioglycosides **10a** and **10d** are competitive inhibitors of hOGA.

![Dixon plots for compounds **10a** and **10d** against hOGA.](fchem-07-00533-g0002){#F2}

Then, compounds **10a**, **10d**, and **16j** were used to investigate the basis for the potency of these thioglycosides against hOGA. Superimposition of the conformations of **10a**, **10d**, and **16j** with hOGA at molecular docking are shown in [Figure 3a](#F3){ref-type="fig"}. The glycosyl moiety from these three compounds was bound into the active pocket of hOGA, and the conformation of glycosyl in **10d** was similar to that of **10a**. Compound **16j** showed a shallower binding in the active pocket compared to **10a**. Moreover, the naphthalimide group of **10a** was found to be closer to the active pocket than both **10d** and **16j**.

![Predicted binding mechanisms of **10a**, **10d** and **16j** with hOGA calculated by molecular docking and MD simulations. Superimposition of the conformations of **10a**, **10d**, and **16j** with hOGA at **(a)** molecular docking and **(c)** 25 ns MD simulations. **(b)** RMSD changes of the three simulated systems (hOGA in complex with **10a**, **10d**, and **16j**). Specific binding patterns of **(d)** hOGA-**10a**, **(e)** hOGA-**10d**, and **(f)** hOGA-**16j** systems after 25-ns MD simulations. Compound **10a** is shown in cyan, **10d** is shown in green, **16j** is shown in yellow (colored by element).](fchem-07-00533-g0003){#F3}

To shed further light on the appropriate binding patterns of **10a**, **10d** and **16j** with hOGA, 25 ns of MD simulations were implemented. As shown in [Figure 3b](#F3){ref-type="fig"} and [Figure S1a](#SM1){ref-type="supplementary-material"}, the root-mean-square deviations (RMSDs) values of these three systems were maintained at around 1.9--3.4 Å, and the dynamic convergences were all achieved after 22 ns of simulations. These results suggested that the systems underwent reasonable conformational change.

The conformations of **10a**, **10d**, and **16j** in complex with hOGA at 25 ns of MD simulations are displayed in [Figures 3c--f](#F3){ref-type="fig"}. As shown in [Figure 3c](#F3){ref-type="fig"}, the glycosyl moiety of **10a** entered more deeply into the hOGA pocket compared to **10d**, and the glycosyl of **16j** only bound at the entrance of the active pocket (shallower than **10d**). These results are consistent with the inhibitory potency of these three compounds against hOGA ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}), and provide a preliminary explanation of the basis for their difference in activity.

[Figures 3d--f](#F3){ref-type="fig"} show the specific binding patterns of **10a**, **10d**, and **16j** with hOGA. The glycosyl moiety of **10a** was found to be tightly bound to the active pocket via H-bonding interactions with residues Gly67, Asn280, Asp285, Asn313, and the oxygen of naphthalimide formed a hydrogen bond with Trp679 ([Figure 3d](#F3){ref-type="fig"}). Moreover, the naphthalimide group of **10a** established van der Waals interactions with Glu677 and π-π stacking interactions with Trp679 ([Figure 3d](#F3){ref-type="fig"}). As a comparison, affected by the larger 4-piperidyl group on the naphthalimide, the binding affinity of **10d** has a specific degree of reduction ([Figure 3e](#F3){ref-type="fig"}). In particular, the glycosyl moiety of **10d** formed four hydrogen bonds (\< **10a**, which possessed five hydrogen bonds) with residues Asn280, Asp285. Furthermore, the naphthalimide of **10d** formed a H-bonding interaction with Glu677 and π-π stacking interactions with Trp660 and Trp 679 ([Figure 3e](#F3){ref-type="fig"}). These binding interactions may have resulted in the 2.3-fold decrease in inhibitory potency compared to **10a** (*K*~i~ = 0.61 μM) and **10d** (*K*~i~ = 1.42 μM). The large benzamido group of **16j** led to the inability of the glycosyl moiety to bind well at the hOGA active pocket, thus only forming two hydrogen bonds with Asp285 and Trp645. This result may explain the basis for the loss of inhibitory activity of **16j**.

Conclusion {#s3}
==========

In summary, a series of novel and readily available thioglycosyl--naphthalimides derivatives were designed and synthesized as effective hOGA inhibitors. Remarkably, thioglycosides **10a** (*K*~i~ = 0.61 μM) and **16l** (*K*~i~ = 0.72 μM) displayed higher inhibitory potencies toward hOGA and exhibited excellent selectivity over HsHexB (Ki \> 100 μM). Moreover, a new method for the synthesis of ureido glycosides was obtained by reaction of trichloroethyl carbamates and primary amines under room temperature and normal pressure without catalyst. Furthermore, molecular docking and MD simulations were performed to investigate the basis for the potency of these thioglycosides for hOGA. This work sheds light on the structure-activity relationship of these thioglycosyl--naphthalimides against hOGA, and provides useful information for the further design and development of hOGA-related drugs.

Materials and Methods {#s4}
=====================

Chemistry
---------

All reagents and solvents were purchased from commercial sources and were used without further purification. The progress of reactions was routinely checked by thinlayer chromatography (TLC) on silica gel GF254 plates with detection by charring with 15% (v/v) H~2~SO~4~ in MeOH or by UV light (254 nm). ^1^H NMR and ^13^C NMR spectra were recorded on a Bruker AVANCE600 spectrometer with TMS as an internal reference and chemical shifts were reported in ppm (δ). High-resolution mass spectra (HRMS) was collected on a micro TOF-Q mass spectrometer of Bruker.

The specific synthetic procedures and characterization data for all the synthesized compounds can be found in [Supporting Information](#SM1){ref-type="supplementary-material"}.

Biology
-------

### Enzyme Preparation

Human O-GlcNAcase (hOGA) was expressed in *Escherichia coli* BL21(DE3) and purified according to previous methods (Kong et al., [@B19]). Human β-N-acetylhexosaminidase B (HsHexB) was overexpressed in *Pichia pastoris* and then purified as described previously (Shen et al., [@B28]).

### Enzyme Inhibitory Activity Test

All target compounds were evaluated for their inhibitory activities against hOGA and HsHexB in end-point experiments. 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide (4-MU-GlcNAc) was used as substrate. In a final assay volume of 100 μL, inhibitor and substrate (40 μM) were mixed with Britton-Robinson buffer (hOGA, pH 6.5; HsHexB, pH 4.5) and enzyme; then, the assay components were incubated at 30°C for 30 min. Subsequently, the enzymatic reaction was terminated by the addition of 100 μL 0.5 M Na~2~CO~3~ solution. The fluorescence of the liberated 4-methylumbelliferone (Mu) was quantified at an excitation of 366 nm and emission of 445 nm on a Varioskan Flash microplate reader (Thermo Fisher Scientific, USA). To determine the inhibition constant (*K*~i~), Dixon plots were performed by changing the concentration of the 4-MU-GlcNAc (40, 20, and 10 μM).

Computational Methods
---------------------

### Molecular Docking

In this study, Sybyl 7.3 Software (Tripos Associates, [@B33]) was used for molecular docking. The crystal structure of the hOGA-PugNAc type inhibitor (PDB ID: 5M7T) (Roth et al., [@B27]) was obtained from the Protein Data Bank (<http://www.rcsb.org/pdb>) and selected as the starting model for docking. Before docking calculations, all water molecules were removed and missing hydrogen atoms were added to the protein. The MMFF94 force field was used to optimize the inhibitors to gain low energy conformations. Subsequently, the ligand mode was applied to generate the appropriate putative ligand pose (protomol), which was used for molecule docking (Jain, [@B15]; Welch et al., [@B35]). Finally, the protein--ligand complexes were achieved using the Surflex--Dock algorithm (ring flexibility was considered and default settings were chosen for the remaining parameters).

### Molecular Dynamics (MD) Simulations

MD simulations of three systems (hOGA in complex with **10a**, **10d**, and **16j**) were performed after molecular docking in the Amber14 package (Case et al., [@B5]). For each system, AMBER03 force field (Duan et al., [@B9]) and GAFF force field (Wang et al., [@B34]) were selected for the protein and the ligand, respectively. This complex system was immersed in a truncated octahedral box with TIP3P water molecules, and an appropriate number of counterions (Cl^−^ or Na^+^) were added to achieve electrostatic neutrality. Subsequently, two stages of energy minimizations were conducted using the Sander module. The water molecules and the ligand were minimized by restraining the protein; then 2,500 cycles of the steepest-descent method and 2,500 cycles of the conjugated gradient algorithm were used to minimize all atoms of the systems. After that, the system was gradually heated from 0 to 300 K in the NVT ensemble and equilibrated to 300 K. Finally, full MD simulations were performed for 25 ns at a temperature of 300 K and a pressure of 10^5^ Pa, employing the PMEMD module in Amber14. The long-range electrostatic interactions under periodic boundary conditions were accounted for using the particle mesh Ewald (PME) method (Darden et al., [@B7]).
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